Methods of treating sickle cell disease

• US 10,450,375 B2
• Filed: 11/03/2004
• Issued: 10/22/2019
• Est. Priority Date: 04/13/2001
• Status: Expired due to Term

• Current Assignee: Icahn School of Medicine at Mount Sinai (The Mount Sinai Health System, Inc.)
• Original Assignee: Icahn School of Medicine at Mount Sinai (The Mount Sinai Health System, Inc.)
• Inventors: Frenette, Paul S., Coller, Barry S., Turhan, Aslihan
• Primary Examiner(s): Popa, Ileana
• Application Number:
  US10/980,496
• Publication Number:
  US 20050112124A1
• Time in Patent Office: 5,466 Days
• Field of Search: None
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: C07K 16/241 Tumor Necrosis Factors
• CPC Class Codes: C07K 16/2839 against the integrin superfamily
• CPC Class Codes: C07K 16/2851 against the lectin superfamily, e.g. CD23, CD72

Abstract

The present invention relates to methods of treating sickle cell disease comprising reducing, in a subject in need of such treatment, the adherence between sickle RBCs and leukocytes. It is based, at least in part, on the discovery that leukocytes play a direct role in the initiation of venular occlusion. The present invention further provides for methods for identifying agents which decrease SS-RBC/leukocyte adherence and for animal models which may be used to further elucidate the mechanism of vaso-occlusion in sickle cell crises.

Claims

1. A method of treating a sickle cell disease subject in vaso-occlusive crisis comprising administering an E-selectin inhibitor that interacts with a calcium-binding lectin domain of E-selectin in an amount effective to treat the subject.